71 results
424B3
UBX
Unity Biotechnology Inc
8 Dec 23
Prospectus supplement
4:39pm
negatively impact quality of life, are typically chronic, and progress from the time of onset until death. It is estimated that providing healthcare
8-K
EX-99.2
bls01cd7rtlqp082 y0
24 Apr 23
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:05am
8-K
EX-99.2
dmnbl02
1 Nov 22
UNITY Biotechnology Announces Positive 24-Week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:00am
424B5
s91broc4
25 Oct 22
Prospectus supplement for primary offering
9:39pm
424B5
wckn4fpw
19 Aug 22
Prospectus supplement for primary offering
8:42am
424B5
ot9kj d3ajxm1w2gu
19 Aug 22
Prospectus supplement for primary offering
8:37am
424B5
oqq4jfw3 ip35yq3
16 Aug 22
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.2
hdoiw 6jnn
12 Aug 22
UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
7:18am